Although its direct therapeutic impact on osteoporosis has yet to be fully elucidated, recent studies have reported that MitoQ inhibits ferroptosis in chondrocytes via activation of the NRF2–Parkin signaling axis, thereby demonstrating potential therapeutic relevance [137]. This evidence concerns the gene NFE2L2 and osteoporosis.